In an in vivo study using CRISPR-Cas9 in transplanted B16 melanoma tumors in mice, Ptpn2 deletion in cancer cells has been shown to improve tumor response to immunotherapy, including an anti-PD-1 antibody and a tumor cell vaccine (GVAX) (60). Here, PTPN2 is linked to neoplasm.